Medexus Pharmaceuticals Inc News - MDP

Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders

TORONTO and CHICAGO and MONTREAL, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy

MONTREAL, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results

TORONTO and CHICAGO and MONTREAL, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Reports Health Canada Approval of Gleolan® (5-ALA) for Use in Guided Surgical Resection of High-Grade Gliomas

TORONTO and CHICAGO and MONTREAL, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants

TORONTO and CHICAGO and MONTREAL, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medication...

MONTREAL, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Announces New U.S. Ticker “MEDXF” on the OTCQX

MONTREAL, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of...

Strong organic growth across all key product lines, including recently acquired IXINITY® Generated $4.1...

Medexus Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th

MONTREAL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Pharmaceuticals Schedules First Quarter Fiscal 2021 Conference Call

MONTREAL, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Pub...

MONTREAL, July 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter o...

Transformative acquisition of IXINITY® completed February 28, 2020 Fiscal 2020 Metoject® unit market demand...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medexus Pharmaceuticals Inc (MDP)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MDP News

Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders

Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy

Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results

Medexus Reports Health Canada Approval of Gleolan® (5-ALA) for Use in Guided Surgical Resection of High-Grade Gliomas

Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medication...

Medexus Announces New U.S. Ticker “MEDXF” on the OTCQX

Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of...

Medexus Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th

Medexus Pharmaceuticals Schedules First Quarter Fiscal 2021 Conference Call

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Pub...

Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter o...

Medexus Pharmaceuticals Schedules Fiscal Year 2020 Conference Call

Medexus to Present at the Virtual Summer Summit on June 10th

Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment

MDP Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medexus Pharmaceuticals Inc (MDP) News

Medexus Pharmaceuticals Inc (MDP)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MDP News

Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders

Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy

Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results

Medexus Reports Health Canada Approval of Gleolan® (5-ALA) for Use in Guided Surgical Resection of High-Grade Gliomas

Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medication...

Medexus Announces New U.S. Ticker “MEDXF” on the OTCQX

Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of...

Medexus Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th

Medexus Pharmaceuticals Schedules First Quarter Fiscal 2021 Conference Call

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Pub...

Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter o...

Medexus Pharmaceuticals Schedules Fiscal Year 2020 Conference Call

Medexus to Present at the Virtual Summer Summit on June 10th

Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment

MDP Discussion

Your Recent History